Andrew Kuykendall, MD, discusses data from a phase 2 trial of fedratinib for the treatment of myeloproliferative neoplasms.

The FDA has cleared investigational new drug applications and handed out fast track designations. Plus, data shows promise for novel therapies in hard-to-treat cancers.

ADRX-0706, a Nectin-4-targeted antibody-drug conjugate, has earned FDA fast track designation in advanced cervical cancer.

The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of ...

During a live event, Daniel M. Geynisman, MD, and participants discussed which efficacy end points they value and how they ...

Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the IsKia, MASTER, and CONCEPT clinical trials ...

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with ...

The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in ...

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer ...

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in ...